(Reproduced by permission from Medicare Focus, August, 1997, pp. 49 - 51.)

Medicare Part A
Local Medical Review Policy

Syphilis Tests; Qualitative (e.g., VDRL, RPR)

Policy Number: 96-12

Description

86592 Syphilis tests; qualitative (e.g., VDRL, RPR, ART)


Type of Bill: 13X, 14X, 22X, 23X, 71X, 74X, 75X

Revenue Codes: 300-319

Indications and Limitations

Syphilis testing is performed to:


A qualitative syphilis test is covered under Medicare Part A when it is considered medically reasonable and necessary for the following:


HCPCS Codes: 86592

Diagnosis Codes for Coverage

ICD-9-CM Code Description
042 Human Immunodeficiency Virus (HIV) Infection
054.10
054.11
054.12
054.13
054.19
Viral Diseases Accompanied by Exanthem
078.0
078.1
Other Diseases Due to Viruses and Chlamydiae
090.0 - 099.9 Syphilis and Other Venereal Diseases
104.0 Other Spirochetal Diseases
131.00 - 131.9 Other Infectious and Parasitic Diseases
331.0
331.2
Hereditary and Degenerative Diseases of the Central Nervous System
356.0
356.9
Disorders of the Peripheral Nervous System
614.0 - 616.9 Inflammatory Diseases of Femal Pelvic Organs
760.2 Maternal Causes of Perinatal Morbidity and Mortality
V01.6 Persons With Potential Health Hazards Related to Communicable Diseases
V22.0
V22.1
V22.2
Persons Encountering Health Services in Circumstances Related to Reproduction and Development

ICD-9 diagnosis codes should be used at their highest level of specificity.

Category: Pathology and Laboratory

Reason for Denial

Routine screening

Noncovered Diagnosis Codes

Any diagnoses other than those listed will be denied without additional documentation.

Sources of Information

Diagnostic Tests Handbook, Springhouse Corporation, 1987
Laboratory and Diagnostic Tests, Fifth Edition, Lippincott, 1996
Other Carriers' Policies

Coding Guides

Use CPT code 86592 when billing for a qualitative syphilis test.

Documentation Required

ICD-9-CM diagnosis codes are required on claim.

Medical records must clearly document the medical necessity for the test and the frequency of the test.

If documentation is requested for review, submit the following:


Comments

This policy is being adapted from the Carrier policy. It does not represent the sole opinion of the Intermediary/Medical Director. This policy was developed in consultation with the medical community and the Carrier Advisory Committee.

Approval Dates

Date of Notice and Comments: April 3, 1996
Notice Period Date: October, 1996
Effective Date of Policy: November 1, 1996